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Background: To initiate immunity, dendritic cells (DCs) capture antigens or
viruses at body surfaces, undergo maturation to express T-cell costimulatory
molecules, and then migrate to lymphoid organs. DCs at body surfaces can
capture human immunodeficiency virus 1 (HIV-1), but mature DCs do not
support replication of the virus unless T cells are added. The initial site for
HIV-1 replication remains unknown and it is unclear whether replication can
take place in DCs or whether the virus must first be transmitted from DCs to
T cells.
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Results: We generated mature DCs from monocyte precursors. Upon infection
with HIV-1, reverse transcription was completed only when T cells were added.
When the reverse transcriptase inhibitor azidothymidine was added to the DCs
during exposure to HIV-1, the DCs remained fully infectious, as long as the drug
was removed just before culturing the DCs with T cells. HIV-1 variants that
were engineered to undergo only one cycle of replication were able to infect
DCs and replicate once in these cells. When T cells were added, newly
produced HIV-1 Gag protein was exclusively localized to the DCs. With wildtype virus, subsequent rounds of replication took place in T cells. Soluble CD40
ligand (CD40L) and CD40L-transfected fibroblasts stimulated HIV-1 replication
in purified mature DCs.
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Conclusions: Mature DCs provide a drug-resistant reservoir for HIV-1. This
reservoir is activated within DCs by CD40L and upon interaction with T cells,
and the virus then spreads rapidly to other T cells.

Background
During the early stages of infection, HIV-1 probably
exploits the antigen-presentation ability of dendritic
cells (DCs). At body surfaces, DCs are specialized to
capture and process antigens but the cells also express
the important coreceptors for HIV-1 entry — CD4 and
the chemokine receptor CCR5 [1–3]. These DCs are
termed ‘immature’ because, at this stage, they do not
express the high levels of the cell surface molecules
(such as, CD40, CD54, CD86) that are required for
potent T-cell stimulation. Immature DCs selectively
capture macrophage (M)-tropic strains of HIV-1 [2,4,5]
(Figure 1), which predominate during transmission of the
virus [6,7].
Upon mobilization from a body surface, the DCs enter
the lymph to migrate to lymphoid organs [8–12]
(Figure 1). The cells also mature to express T-cell stimulatory molecules [13,14]. The fully matured DCs activate
antigen-specific T cells in lymphoid tissues [15]. Activated T cells are in turn permissive for HIV-1 replication
and die by apoptosis [16]. Purified mature DCs are
unable to support viral replication, however [5,17–22], as

the life cycle of the virus appears to be blocked shortly
after entry. Mature DCs therefore support the early but
not the later stages of reverse transcription of the virus,
and the formation of these early transcripts requires functional chemokine receptors on DCs [5,23].
Nevertheless, when mature DCs are incubated with
virus and then mixed with T cells, as would occur when
DCs stimulate immunity in lymph nodes, a strong productive infection occurs (Figure 1). This infection is
noteworthy because of its rapidity and its magnitude, and
because it does not require addition of mitogens, interleukin-2 (IL-2) or heterologous sera [5,17,19,20,22].
Here, we address the events that take place when mature
DCs interact with T cells in culture. Large numbers of
mature DCs were generated from blood monocytes using
a standard tissue culture system [24–26] and these cells
were further purified on the basis of high expression of
CD83 [25,27]. We used pseudotyped variants of HIV-1
that are only able to undergo one cycle of replication to
show that mature DCs are responsible for the first cycle
of HIV-1 replication, whereas subsequent cycles occur
primarily in T cells.

22

Current Biology, Vol 9 No 1

Figure 1
A diagram of the proposed function of
immature and mature DCs at body surfaces
and lymphoid organs, respectively. Tissue
culture studies indicate that immature DCs
directly capture and replicate M-tropic — R5
— viruses, whereas mature DCs support HIV1 replication only when T cells are present.
In vivo, immature DCs are found in the
stratified, skin-like epithelia in the vagina,
cervix and anus through which HIV-1 is
probably transmitted. During migration into
the lymph and upon reaching the T-cell
areas of lymph nodes, the DCs mature and
become potent stimulators of the immune
response in lymphoid organs. In the lymph
node, mature DCs would encounter T cells,
setting up the kind of cellular environment
that is permissive for HIV-1 replication.
B, B-cell areas of lymph nodes.
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Figure 2
Mature, HIV-1-pulsed DCs transmit virus to syngeneic (syn) and
allogeneic (allo) T cells. Purified DCs were pulsed for 2 h with wildtype (BaL) HIV-1, washed and cultured for 24 h. The DCs were
washed again and co-cultured with unstimulated T cells or activated T
cells (Tbl) at a ratio of 1:3. (a) The cells were collected 14 h and 48 h
after co-culture, and the lysates analyzed by PCR for early and
complete reverse transcripts using R/U5-specific and LTR/gagspecific primers respectively. Reverse transcripts were compared with
standards corresponding to graded doses of amplified DNA from
ACH-2 cells that harbor one copy of viral DNA per cell.
(b) Supernatants were collected 4, 7 and 9 days after DC–T-cell coculture, and p24 antigen levels measured by enzyme-linked
immunosorbent assay (ELISA).
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Mature DCs were purified from cultures of blood monocytes that had been treated with granulocyte macrophage
colony-stimulating
factor
(GM-CSF),
IL-4
and
lipopolysaccharide (LPS) to drive maturation into DCs.
When incubated or pulsed with HIV-1 for 2 hours, the
mature DCs did not directly replicate virus, although a
strong infection took place when T cells were added, with
activated T cells having a greater effect than unstimulated
T cells (Figure 2). In this and other experiments, we
removed adsorbed virus by trypsinizing the DCs and then
culturing for 24–48 hours prior to washing and addition of
T cells. When the infection was monitored at the level of
production of HIV-1 DNA, the purified DCs did not accumulate complete reverse transcripts, that is, sequences
comprising the long terminal repeat/gag region (LTR/gag;
Figure 2a). LTR/gag sequences quickly appeared upon
the addition of T cells, either unstimulated T cells from
blood or T-cell blasts activated in a mixed leukocyte reaction (Figure 2a) or with phytohemagglutinin (PHA; data

not shown). By day 4 of the DC–T-cell co-culture, the p24
Gag protein began to accumulate in the medium
(Figure 2b). The T cells were permissive whether syngeneic or allogeneic (that is, matched or mismatched
human leukocyte antigen (HLA)-DR3, respectively) to
the infected DCs, and stimulated T cells (T blasts) produced higher levels of virus (Figure 2). Purified, monocyte-derived, mature DCs therefore behave comparably to
DCs from other sources [5,17,19,20,28,29], that is, the cells
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do not replicate virus directly but do so upon co-culture
with T cells.
HIV-1 in purified, mature DCs represents a drug-resistant
reservoir of infectious virus

Previous work had shown that HIV-1 entered mature DCs
as long as the appropriate chemokine receptors were
expressed, but the life cycle of the virus was then blocked
after the early stages of reverse transcription [2,23]. Virus
replication resumed when the DCs were co-cultured with
T cells. Following a 2 hour incubation of mature DCs with
virus, reverse transcription began (as detected with R/U5
primers which detect the early stages of reverse transcription), but complete LTR/gag-containing sequences did
not accumulate [23]. Before determining how infection
was stimulated in co-cultures of mature DCs and T cells,
we had to formally rule out that trace — but infectious —
levels of reverse transcription were taking place in DCs.
Therefore, we infected and cultured the DCs in the
reverse transcriptase inhibitor azidothymidine (AZT) prior
to mixing with T cells. AZT is more efficient in blocking
late stages of reverse transcription than early stages, but
the effect of AZT is reversible [30].
When DCs were pulsed with HIV-1, the early stages of
reverse transcription were detected using primers for
R/U5-containing sequences, and these sequences reproducibly persisted for 72 hours (Figure 3a). In contrast,
HIV-1-infected T blasts initially had lower levels of R/U5
sequences than HIV-1-infected DCs, but the signal
increased with time because the virus was replicating
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(Figure 3a). Next, DCs were pretreated with 1 µM AZT
before and during the pulse with HIV-1, washed and then
cultured for 36 hours with the drug. After 36 hours, AZT
was washed out and uninfected T blasts were added to the
infected DCs. Figure 3b shows that the DCs that had been
treated for 36 hours with AZT (0–36 hours) were still able
to transmit infection to T cells. This was documented both
at the level of proviral DNA (Figure 3b) and by the release
of p24 antigen into the medium (Figure 3c) in more than a
dozen experiments. In contrast, if AZT was added to the
DC–T-cell cultures at 36 hours and kept in the medium
for the next 96 hours (36–132 hours), virus replication was
blocked, as monitored by the appearance of LTR/gag-containing sequences (Figure 3b) and the accumulation of p24
(Figure 3c). We found that DCs can transmit infection to
T cells even 3 days after exposure to virus (data not
shown), although much less efficiently, presumably
because the DCs were dying. These results indicate that
DCs infected in the presence of AZT remained infectious
once the AZT was removed. Therefore, we set up experiments to determine the site where virus replication begins
when DCs are added to T cells, that is, whether HIV-1
replicates in the DCs or in the T cells.
Infection of DCs with pseudotyped viruses

HIV-1 particles can be pseudotyped by envelope glycoproteins such as vesicular stomatitis virus glycoprotein
(VSV-G) [31,32]. Pseudotyped viruses allow the study of
early events in viral transmission, because the viruses are
only capable of one cycle of replication due to their
chimeric form. Using a VSV-G-pseudotyped virus, the

DC

Tbl

12 24 48 72

12 24 48 72

(a)
Time (h)

Standards
10 102 103 104

R/U5

(b)

AZT
T blasts

None
– +

0–36 h
– +

36–132 h Standards
– + 10 102 103 104

R/U5

(c)

8000

p24 (pg/ml)

Figure 3

6000

No AZT
AZT (0–36 h)
AZT (36–132 h)

4000

2000

LTR/gag
0
DC

DC + T blasts

Current Biology

HIV-1 in virus-pulsed DCs is present in a drug-resistant form.
(a) Longevity of R/U5 reverse transcripts in HIV-1-infected cells.
Mature DCs and activated T cells were infected with HIV-1. At the
indicated times, cells were lysed and DNA amplified by PCR for R/U5
sequences (5 × 104 cells were analyzed per lane). (b,c) AZTpretreated mature DCs are competent to transfer HIV-1 to T cells.
Mature DCs were incubated for 30 min with or without 1 µM AZT.
Cells were infected with HIV-1 and maintained for 36 h in the

presence or absence of AZT. Cultures were washed to remove AZT,
and the DCs were cultured with or without non-infected T blasts. To
block residual AZT, dNTPs (25 µM) were added to the cells. In one
set of cultures, AZT was added at 36 h (36–132 h) during the addition
of T cells. In (b), HIV-1 reverse transcripts were amplified after 72 h of
co-culture, while in (c) productive infection was measured using ELISA
for p24 antigen levels in the culture medium. Standards in (a,b)
correspond to those used in Figure 2.
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Infection of DCs with (a) VSV-pseudotyped HIV-1 and (b) wild-type
(BaL) HIV-1. Mature DCs, sorted as CD83+, were treated with 10 mM
NH4Cl for 1 h before and during a 2 h pulse with virus. The DCs were
washed, cultured for 24 h with or without NH4Cl, washed again, and T
blasts that had been treated with or without NH4Cl were added. After
72 h of co-culture, cell lysates were analyzed by PCR for detection of
reverse transcripts. In (a), to determine that the samples we amplified
for reverse transcripts contained the same amount of DNA, we also
amplified HLA-DQ sequences as a control. Standards correspond to
those used in Figure 2.

first cycle of HIV-1 replication could therefore be followed to determine whether it occurred in DCs or T cells.
VSV-G-pseudotyped virus enters cells through an endocytic, pH-sensitive pathway [33]. To test whether HIV1–VSV required low pH levels for the infection of DCs,
the cells were infected in 10 mM NH4Cl, an inhibitor of
endosomal acidification. CD83+ DCs were pretreated for
1 hour with NH4Cl and then pulsed with HIV-1–VSV for
2 hours in the continued presence of NH4Cl. The DCs
were washed and incubated for 24 hours before addition to
T blasts, which had also been treated or untreated with
NH4Cl. After 72 hours, the cells were harvested and analyzed by PCR. NH4Cl inhibited infection when it was
applied with HIV-1–VSV to the DCs (Figure 4a, lane 4)
but not when it was added to the DC–T-cell co-culture
(Figure 4a, lane 3). This means that infection was taking
place in the DCs, and not in the T cells. To rule out toxicity, we showed that NH4Cl treatment did not significantly
inhibit infection by an HIV-1 variant that was pseudotyped with the pH-insensitive JRFL M-tropic envelope
(data not shown) or by wild-type (BaL) HIV-1 (Figure 4b).
To verify that the DCs were supporting viral protein synthesis upon co-culture with T cells, samples of the cultures were cytospun onto slides and immunolabeled for
HIV-1 Gag with anti-p24 monoclonal antibody. The
mature DCs, selected initially on the basis of expression
of the CD83 marker, were double-labeled for a second
marker, DC-LAMP, which is localized to the lysosomes of

DCVSV + CD40L

DCBaL + CD40L

Current Biology

Immunostaining of infected DC–T-cell co-cultures. Sorted CD83 +
cells were infected with either (a,c) HIV-1–VSV or (b,d) wild-type
(BaL) HIV-1. After 24 h, T blasts were added and the DC–T-cell
mixtures cultured for 4 days (a,b), or the DCs were cultured with
CD40L-transfected fibroblasts for 4 days (c,d). Cytospins were
stained for p24 expression (brown) and for the lysosomal marker that
is expressed in mature DCs, DC-LAMP (blue). (a) With HIV-1–VSV,
DCs became infected upon co-culture with T blasts but the T blasts
(arrows) were not infected. (b) With wild-type HIV-1, DCs also
become infected upon co-culture with T blasts, but the T cells are
p24+ (T blasts, arrows). (c,d) Likewise, CD40L-expressing cells
activate HIV-1–VSV and wild-type HIV-1 infection of DCs.

mature DCs [34]. All of the p24+ cells were large, irregularly shaped and expressed DC-LAMP (Figure 5). In contrast, when DCs were infected with wild type HIV-1, so
that cell–cell transmission of the infection could occur,
round p24+, DC-LAMP– T cells predominated (Figure 5b;
note lack of blue DC-LAMP staining on the small, brown
cells as marked by arrows).
These immunocytochemical observations were extended
using fluorescence-activated cell sorting (FACS)
approaches. When DCs were pulsed with wild-type virus
and cultured with T cells for 4 days, many p24+ cells were
evident and the vast majority were CD3+CD83–, that is, T
cells (Figure 6a). When VSV-G-pseudotyped virus was
used to infect DCs, few infected cells were evident
(Figure 6a). In these experiments, the T cells proliferated
and vastly outnumbered the DCs. We conclude, therefore,
that infection began in the DCs and, with wild-type virus,
the infection continued primarily in T cells.
Ligation of CD40 on DCs triggers productive HIV-1
infection

To identify a mechanism whereby T cells could be activating HIV-1 replication in DCs, we considered the role
of CD40 ligand (CD40L), a tumor necrosis factor (TNF)
family member that is expressed on activated T cells
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Effect of CD40 ligation on infected DCs. (a) CD83+ DCs were
infected with wild-type (BaL) HIV-1 and then cultured at different ratios
with irradiated (3000 rads) CD40L-transfected cells, as indicated (for
example, 1:10 = 1 CD40L cell to 10 DCs) or with the control,
irradiated non-transfected fibroblasts (fib; 1:10). Standards
correspond to those used in Figure 2. (b) CD83+ DCs were infected
with pseudotyped virus and cultured as indicated: 1 irradiated CD40L
cell to 10 DCs in the absence or presence of the anti-CD40L
monoclonal antibody LL48 (10 µg/ml); soluble CD40L (sCD40L;
1:100 dilution of baculovirus supernatant); anti-CD40 monoclonal
antibody 89 (anti-CD40; 10 µg/ml). After 72 h, cells were harvested
and analyzed for the presence of LTR/gag sequences.
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FACS analysis of HIV-1-infected DCs cultured with T blasts or CD40Lexpressing cells. Sorted CD83+ cells were infected with wild-type (BaL)
HIV-1 or HIV-1–VSV. (a) T blasts or (b) CD40L cells were added to the
infected DCs after 24 h. After 4 days, the cells were collected, doublelabeled with anti-p24 antibody conjugated to fluorescein isothiocyanate
(FITC) and either anti-CD3 antibodies (for T cells) or anti-CD83
antibodies (for DCs) conjugated to phycoerythrin (PE).

[35,36]. CD40L maintains the viability and function of
mature DCs in culture [37,38]. We first tested whether
fibroblasts transfected with CD40L could activate the
first cycle of viral replication in HIV-1-pulsed, mature
DCs. Again, we purified CD83+ mature DCs by FACS
prior to co-culture for 4 days with stably transfected, irradiated CD40L-expressing fibroblasts. Figure 5c,d shows
that crosslinking with CD40L-expressing cells induced
productive infection in mature, CD83+ and DC-LAMP+
DCs infected with pseudotyped and wild-type virus.
Quantitation of the infected DCs after CD40 crosslinking
was assessed by FACS (Figure 6b). The results of several
experiments indicated that the percentage of DCs replicating HIV-1 was in the range of 1 to 15%. Figure 7
shows that complete reverse transcripts (detected using
LTR/gag primers) were undetectable in the cultures containing DCs alone, but were increased in the
DC–CD40L co-cultures or in DCs cultured with soluble
CD40L (Figure 7b, lanes 2,3). A ratio of 1 CD40Lexpressing fibroblast per 10 DCs was optimal (Figure 7a).
Again, CD40L activated HIV-1 replication in purified

DCs following infection with either wild-type (Figure 7a)
or pseudotyped viruses (Figure 7b). The effect of
CD40L was blocked by more than 50% by the addition of
anti-CD40L antibody (Figure 7b, lane 5). Interestingly, a
blocking anti-CD40 antibody could sustain the viability
of the DCs but, unlike CD40L, this only modestly
enhanced HIV-1 infection of DCs (Figure 7b, lane 4).

Discussion
Mechanism of imitation of HIV-1 replication in mature DCs
following co-culture with T cells

It is important to study the interaction of HIV-1 with
DCs, because these cells capture viruses and other antigens at body surfaces and initiate specific immunity in
the draining lymphoid tissue (reviewed in [1]). Specific
immunity includes responses in CD4+ T cells, the major
site for HIV-1 replication in patients. Initially, there were
discordant findings on the capacity of DCs to support
HIV-1 replication. Some reports concluded that DCs
were explosive sites for infection, and others concluded
that DCs were not a site for infection. Subsequently, it
became apparent that HIV-1 does not replicate in mature
DCs, which are unusually potent at stimulating T-cellmediated immunity. DCs can support HIV-1 replication
under two circumstances, however: either as highly
enriched populations of immature DCs [2,4,5,39], that is,
those DCs at the stage of development where they can
capture and process antigens but are not yet endowed
with full T-cell stimulatory activity; or as mature DCs
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Figure 8
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Diagram of possible DC mechanisms in transmitting HIV-1. (a) Passive
transmission of viral particles trapped on the surface of DCs to T cells.
(b) Fusion of viral particle at DC membrane via HIV-1 coreceptors and

transmission to T cells upon DC–T-cell contact. (c) Replication of virus
in DCs and transmission to T cells, which take over the infection in the
culture because of higher levels of CD4 and CCR5 than mature DCs.

that are co-cultured with T cells [5,17–20,28,29,40,41]. In
the latter instance, the bulk of the HIV-1 replication is
taking place in CD3+ T cells [17,18], or in DC–T-cell
syncytia [19,20,42].

and from skin [19,20], that is, the cells do not replicate
HIV-1 directly but do initiate a strong infection upon coculture with T cells. Prior to encounter with T cells, the
infectious virus in the DCs is in an AZT-resistant state
(Figure 3), confirming that the viral life cycle is blocked in
DCs at a very early stage in reverse transcription [5].

The roles played by DCs and T cells during infection of
DC–T-cell mixtures has been unclear. It is important to
decipher underlying mechanisms, because during pathogenesis (Figure 1 and see below), it is likely that HIV-1 is
captured at body surfaces by immature DCs which then
mature as they migrate to the lymphoid organs to engage
and activate T cells. In other words, during acute infection
with HIV-1, mature virus-exposed DCs should encounter
T cells in lymphoid tissues. We have addressed the three
main possibilities whereby DCs might initiate infection
during T cell co-culture: the virus could simply be
adsorbed to the DC surface and enter the T cell directly
(Figure 8a); the virus could fuse with the DC but remain
at the surface and be transmitted to the T cell upon
DC–T-cell contact (Figure 8b); or the virus might undergo
a single cycle of replication in DCs and then infect T cells
(Figure 8c). Our findings reveal the latter to be the
pathway that occurs in our tissue culture model, and we
show that the block to viral replication in mature DCs can
be overcome by co-culture with T cells and by signals
delivered by CD40L. After the first cycle of infection in
the DC, the T cell becomes the major site for replication.
Mature DCs were generated from blood monocytes and
further purified by FACS on the basis of CD83 expression
[27]. The CD83+ cells had all the expected characteristics
of mature DCs [25,26], expressing high levels of the
human leukocyte antigen HLA-DR and of CD86, and
having several features not found in immature DCs such as
DC-LAMP expression and very potent stimulating activity
for the mixed leukocyte reaction. With these monocytederived DCs, we confirmed the results of prior studies
using mature DCs isolated directly from blood [5,17,18]

To identify the cell type that initially replicated HIV-1 in
DC–T-cell co-culture, we used pseudotyped virus. The
pseudotyped virus was derived by cotransfecting 293T
cells with separate plasmids encoding viral envelope proteins (from either JRFL or VSV in our studies) and the
envelope-deficient HIV-1 NL4.3. These pseudotyped
viruses could therefore undergo only a single cycle of virus
replication. We found that the first cycle began in the DCs
(Figure 8c) and not in the T cells (Figure 8a,b). NH4Cl,
which blocks the fusion of VSV-G-pseudotyped virus,
only blocked infection of the DC and not the T cell
(Figure 4). When the cells were examined directly, p24
was only being produced in DCs at the single-cell level
(Figure 5). The DCs were mature on the basis of several
markers, notably preselection for CD83 staining and
expression of DC-LAMP.
A major pathway for T-cell-mediated activation of HIV-1
replication in DCs may involve a CD40L–CD40 interaction. CD40 is functionally active in DCs [37,43], whereas
CD40L is expressed by activated T cells. When we tested
the effects of CD40L-transfected fibroblasts or soluble
CD40L, both could trigger the replication of wild-type and
pseudotyped HIV-1 in mature DCs directly. Interestingly,
anti-CD40 monoclonal antibodies had, at best, modest
effects in triggering the first round of HIV-1 replication in
DCs (Figure 7). We considered that CD40L could be the
active molecule for the induction of HIV-1 replication in
DCs by T cells. Addition of anti-CD40L monoclonal antibodies to DC–T-cell co-cultures, however, did not inhibit
replication significantly. The explanation for this may be
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that it is difficult to block the function of CD40L in cultures of growing T cells, or that additional molecules other
than CD40L could be operating on T cells.
Possible in vivo relevance

The distribution of DCs in vivo, coupled with these findings and other studies [4,5,19,28,29,39] provide a model
whereby DCs are critical for the transmission and early
replication of HIV-1 in infected individuals. At body surfaces, such as the vagina, cervix and anus, immature DCs
are found and can begin to replicate virus [5,29,44]. The
virus that is produced is highly infectious for T cells [5]
and macrophages [45].
In addition to picking up viruses and other antigens at
body surfaces, DCs can undergo two other sets of changes:
one is to leave the body surface and migrate to the lymph
node via the lymphatic system; the other is to mature to
become potent stimulators of immunity. These two sets of
changes are coordinated, because the levels of CD80,
CD86 and major histocompatibility (MHC) II molecules
are increased when cells are stimulated to migrate from
the skin or are examined in lymph. When immature DCs
are infected and then a maturation stimulus added, HIV-1
replication ceases [5]. Likewise, when mature DCs are
exposed to HIV-1, the virus enters but is blocked at an
early stage of reverse transcription [23,46]. HIV-1 only
replicates when DCs encounter T cells. We now show
that the first cycle of replication occurs in the DCs, but
that the bulk of the subsequent replication occurs in T
cells, which also are a major site for viral replication during
the acute stages of simian immunodeficiency virus (SIV)
infection in macaque lymph nodes [47,48]. We would
argue that the virus preferentially accesses activated T
cells, because T cells have much higher levels of the HIV1 coreceptors CD4 and CCR5 than mature DCs (at least a
log higher fluorescence signal by FACS analysis [3]).
Mature DCs are able to capture virus when they are the
main cell type being exposed to the virus, as would be
expected to occur at a body surface where there are relatively few T cells. The ominous feature is that once the
mature DC encounters a T cell, the interaction between
the two cell types — which is so efficient in generating Tcell-mediated immunity — sets up a permissive environment for the virus without further addition of
experimental stimuli such as IL-2 and mitogens. The T
cell drives the first cycle of replication in the mature DC,
and the DC sustains the activation of T cells for subsequent rounds of replication.
Although we have discussed the exploitation of DCs
during pathogenesis, our findings have another consequence. If single-cycle virus could be delivered to DCs,
virus would not be transmitted to T cells but viral peptides should still be presented efficiently to CD4+ and
CD8+ T cells. For example, influenza-infected DCs elicit
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very strong CD4+ and CD8+ T-cell responses [49]. Our
data show that HIV-1 protein is being synthesized in DCs
(Figure 5,6), so we would expect that these DCs would act
as potent antigen-presenting cells for HIV-1-specific
CD4+ and CD8+ cells. Both types of T cells have been
implicated in resistance to HIV-1.

Conclusions
The DC system of antigen presentation constitutes a
physiological mechanism for activating CD4+ T-cell-mediated immunity. When mature immunostimulatory DCs
are pulsed with HIV-1 in culture, virus replication only
proceeds if T cells are added. Using pseudotyped viruses,
we show that the first round of HIV-1 replication occurs
within the DC. The T cells then serve as permissive hosts
for the virus that is produced by the DCs. We propose that
these events take place in vivo when HIV-1 is captured by
DCs in blood or at body surfaces, and the virus is then
transmitted by DCs to T cells in the T-cell-dependent
regions of lymph nodes.

Materials and methods
Cells
DCs were generated from the blood of normal donors, usually from
buffy coats obtained from the New York Blood Center [5,25,26].
Briefly, peripheral blood mononuclear cells (PBMC) were isolated by
sedimentation in Ficoll-Hypaque, and 5 × 107 PBMC plated in 100 mm
tissue culture plastic dishes in RPMI supplemented with 5% human
serum. After 1 h, the floating cells were removed, and the adherent
cells incubated for 6 days in GM-CSF (100 IU/ml, Leukine; Immunex)
and IL-4 (1000 U/ml; Genzyme). The cells were fed on day 2 and day 4
with the same dose of cytokines. At day 6, most of the non-attached
cells were immature DCs, being CD14–, CD4+, HLA-DR+ and CD86+,
but lacked expression or only had weak expression of the CD83, p55,
DC-LAMP and CD25 markers of mature, more stimulatory DCs. To
promote maturation of the DCs, we replated the cells for 3 days in
6-well plates at 106 cells/well in 3 ml medium supplemented with
cytokines as above and either lipopolysaccharide (LPS; 20 ng/ml) or
monocyte-conditioned medium (MCM) [25,26]. Following maturation,
the DCs expressed higher levels of surface HLA-DR and CD86 and
now expressed CD83 [27] and the DC-LAMP antigen [34], as well as
having strong antigen-presenting capacity in the mixed leukocyte reaction even at ratios of 1 DC to 1000 responder T cells. In many experiments, the purity of the mature DCs was enhanced by sorting CD83+
cells on a FACStarPLUS. T blasts were generated by stimulation of
PBMC with PHA (1 µg/ml; Burroughs Wellcome) for 3 days, or in an
allogeneic mixed leukocyte reaction for 5 days. CD40L-transfected
fibroblasts, anti-CD40 (monoclonal antibody 89), and anti-CD40L
(LL48) antibodies were kindly provided by J. Banchereau.

Viruses and infection of cells
We were kindly provided with a VSV-G expression construct pHCMVG from J. Burns (University of California, San Diego), and the plasmid
expressing JRFL env from N. Landau (Aaron Diamond AIDS Research
Institute, New York). For production of wild-type HIV-1 and pseudotyped viruses, 293 T cells were cotransfected in 100 mm dishes with
20 µg each of envelope-minus proviral DNA (pNL4.3 env minus) and
an envelope expression plasmid or with pNL4.3/BaL DNA using a
calcium phosphate method. The cells were washed and incubated with
10 ml DMEM supplemented with 10% FCS 4 h after transfection. Virus
stocks were prepared by collecting the culture supernatants after 48 h
and filtering them through 0.45 µm Millipore filters. Virus stocks were
stored in aliquots at –80°C. Viral titers (infectious units) were quantitated in HeLa MAGI cells as described by Vodicka et al. [50] and by
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p24 ELISA. DCs were infected with pseudotyped viruses or BaL
grown in mitogen-stimulated PBMC at an multiplicity of infection of
2–20 ng p24 antigen or 103–104 infectious units per 105 cells. To
reduce HIV-1 DNA in the virus-containing supernatants, the latter were
treated with RNAse-free DNA (50 U/ml at room temperature for
30 min). After 2 h at 37°C, non-absorbed virus was washed out and the
cells incubated for the desired time in RPMI 5% human serum.

Detection of HIV-1 in infected cells
To analyze viral DNA, infected cells were collected at the indicated
times, washed twice with PBS, and lysed in lysis buffer (10 mM Tris
HCl pH 8, 1 mm EDTA, 0.001% Triton X100-sodium dodecyl sulphate,
and proteinase K at 1 mg/ml). Samples were incubated at 60°C for 1 h
and at 98°C for 10 min. Reverse transcripts were amplified by PCR,
early transcripts with R/U5 primers (sense, 5′-GGTAACTAGGGAACCCACGT-3′; antisense; 5′-CTGCTAGAGTTTTCCCACTGAC-3′); and
full-length transcripts with LTR/gag primers (sense 5′-GGCTAACTAGGGAACCCACGT-3′; antisense, 5′-CCTGCGTCGAGAGAGCTCCTCTGG-3′). Amplified products were resolved on non-denaturing
8% polyacrylamide gels and visualized by autoradiography of the dried
gels. At different times after infection, aliquots of culture supernatant
were harvested and stored at –20°C. Samples were assayed for p24
antigen by ELISA (Coulter).
Immunohistochemistry was performed on 5 × 103 cells cytospun onto
slides (Shandon). Slides were dried and fixed for 10 min in acetone at
room temperature. For double labeling, the DC-LAMP antigen first was
visualized with monoclonal antibody, kindly provided by S. Lebecque
[34], followed by anti-mouse antibody conjugated with alkaline phosphatase (DAKO) and nitroblue tetrazolium (NBT) as substrate. Then
p24 antigen was identified with rat anti-p24 monoclonal antibody
(Biosource) and anti-rat Ig conjugated with horseradish peroxidase
(Amersham) and diaminobenzamide as substrate. DC-LAMP expression is restricted to mature DCs, where it is confined to perinuclear
lysosomes [34].
Infected cells were fixed with 4% paraformaldehyde in PBS for 30 min
on ice. Cells were permeabilized for 30 min in 1% saponin on ice and
stained with anti-p24 followed by a FITC-labeled secondary antibody
(TAGO), and double-stained with anti-CD3 PE (Becton-Dickinson) or
anti-CD83 PE (Coulter).
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